A comprehensive view of Weight Management Products. This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Morgan Stanley names Wendy's, Jack in the Box, Wingstop as fast-food chains to face pressure from rise in GLP-1 drugs like Ozempic, as people spend less at restaurants; healthier fast-casual restaurants poised to handle looming shift in consumer spending
Published: April 22, 2024 by Quartz
High demand for injectable weight-loss drugs has led to supply issues, with most varieties listed in short supply by the FDA; Eli Lilly reports shortages of its Zepbound and Mounjaro could last until 2025
Published: April 19, 2024 by CBS - 12 WJTV (Jackson, MS)
GlobalData predicts GLP-1 drugs will redefine big pharma sales; Eli Lilly's diabetes drug, Mounjaro, is forecasted to generate US$34.0B by 2029, surpassing the entire 2023 portfolio of Lilly, with the Alzheimer's drug donanemab adding another US$5.0B
Published: April 17, 2024 by FiercePharma
Eli Lilly proposes revisions to FDA guidance addressing obesity, identifying obesity as a chronic disease and requesting updated practices for clinical trials to better address the growing public health crisis
Published: April 12, 2024 by Targeted News Service
Commentary: Excessive costs on GLP-1 medications from Eli Lilly and Novo Nordisk have led to their inaccessibility in low-/middle-income nations; report finds if branded companies were to partner with generics makers, prices could be less than US$1/month
Published: April 08, 2024 by Indian Pharma Industry: Policies

Ask us about our R&D/Patents market view

Trending Chart

Interactive chart with headline count